Deep Apple was created and incubated by Apple Tree Partners (ATP), a leader in life sciences venture capital, with an initial $52 million in Series A funding.

The company's discovery engine is broadly applicable across disease areas and is particularly well-suited to expedited hit-finding against integral membrane proteins. Deep Apple is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders, inflammation, immunology, and endocrine diseases.